Skip to main content
. 2020 May 19;18(3):315–324. doi: 10.5217/ir.2019.09179

Table 4.

Survival According to Tumor Characteristics and Treatment

Variable No. 2-Year survival rate (%)a 5-Year survival rate (%)a P-valueb
Clinical stage < 0.001
 Early 93 82 68
 Advanced 165 56 22
Tumor location 0.700
 Descendent colon 21 75 75
 Blind 40 75 55c
 Transverse colon 21 63 50d
 Rectum 110 61 46
 Ascendant colon 60 60 33
 Sigmoid colon 51 84 19
Tumor size (cm) 0.700
 < 2 11 60 45e
 2–5 86 66 49
 > 5 182 65 39
Metastatic lymph node 0.110
 0 249 60 42
 1–3 29 68 34f
 ≥ 4 26 88 0
Presence metastasis < 0.001
 Negative 204 71 57
 Positive 101 47 0
Distant metastases 0.008
 Lung 15 74 48g
 Liver 41 24 0h
 Lung and liver 9 0 0
 Bone 5 53 0
 Others 29 57 0
Histologic grade 0.170
 Grade 1 195 24 41
 Grade 2 68 70 39
 Grade 3 32 50 37i
Type of chemotherapy 0.150
 Adjuvant 61 61 34
 Neoadjuvant 121 70 40
Scheme of chemotherapy 0.320
 5 FU 22 73 63
 Capecitabine 16 57 57
 Oxaliplatin 64 70 43
 FOLFOX 17 62 31
 XELOX 41 68 0
 Others 3 50 0
a

Kaplan-Meier method.

b

Log-rank test.

c

Maximum survival of 56 months.

d

Maximum survival of 49 months.

e

Maximum survival of 42 months.

f

Maximum survival of 58 months.

g

Maximum survival of 55 months.

h

Maximum survival of 56 months.

i

Maximum survival of 56 months.

5 FU, 5-fluorouracil; FOLFOX, oxaliplatin, 5-FU, and leucovorin; XELOX, capecitabine (Xeloda) and oxaliplatin.